Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 1311, 2005; 10.1373/clinchem.2005.052142
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cantor, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cantor, D.
Related Collections
Right arrow Clinical Immunology
Right arrow Proteomics and Protein Markers
Right arrow Drug Monitoring and Toxicology
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2005;51:1311.)
© 2005 American Association for Clinical Chemistry, Inc.

Letters to the Editor

Reason for Limitations of Heterophilic Blocking Tube Use on Certain Beckman Coulter Access Assays

David Cantor

Scantibodies Laboratory, Inc., 9336 Abraham Way, Santee, CA 92071

The first 20% of the full text of this article appears below.


To the Editor:

A recent Technical Brief by Ellis et al. (1) showed the usefulness of heterophilic blocking tubes (HBTs) in identifying false-positive specimens, thereby providing an estimate of the incidence . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.